Rheumatology Trials Seem Vulnerable to Unblinding: Report
Until more is known about the potential for unblinding, clinicians need to keep in mind that patients and physicians could often guess accurately who was getting placebo or active drug.
MDedge News
source https://www.medscape.com/s/viewarticle/rheumatology-trials-unblinding-seem-vulnerable-2023a1000k1w?src=rss
MDedge News
source https://www.medscape.com/s/viewarticle/rheumatology-trials-unblinding-seem-vulnerable-2023a1000k1w?src=rss
Comments
Post a Comment